Geoff Oxnard
Patrimonio netto: 331 512 $ in data 30/09/2026
Patrimonio netto: 331 512 $ in data 30/09/2026
Geoff Oxnard is Chief Medical Officer & Executive Vice President at Blossomhill Therapeutics, Inc. since 2025.
Formerly, Dr. Oxnard was Vice President & Global Head-Thoracic Cancers at Eli Lilly & Co. from 2023 to 2025 and Senior Vice President & Head-Clinical Development at F.
Hoffmann-La Roche Ltd. from 2021 to 2023.
Education includes undergraduate studies at Harvard University and a doctorate from Pritzker School of Medicine.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 07/08/2026 | 17.785 ( 0,06% ) | 331 512 $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| BLOSSOMHILL THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2025 |
| Società | Posizione | Fine |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/2025 |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 01/09/2023 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pritzker School of Medicine
Pritzker School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for oncology and autoimmune diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale